Anacor Pharmaceuticals, Inc. (ANAC)

[harry crumb]

Earnings!

[2014shelby]

What's the rise for?

[harry crumb]

Great day here. What a bio to own!

[harry crumb]

What power here! Just think a year ago we bought this at 14-15 pps. Go anac an congrats to all others at moving above 50 pps.

[harry crumb]

Check the 1 year chart out. What a beauty it is. Science is always a winner, sooner or later. I remember when AF said to short this, what a dipsh.. That guy is.

[harry crumb]

Anac is fastly becoming a bio powerhouse. Have a few left here at 15 area.

[2014shelby]

Awesome. Thanks for the info

[stocktrademan]

$ANAC DD Notes ~ http://www.ddnotesmaker.com/ANAC

bullish

$ANAC recent news/filings

## source: finance.yahoo.com

Tue, 18 Nov 2014 20:13:29 GMT ~ Growth stocks provide litmus test for stock market


read full: http://www.marketwatch.com/News/Story/Story.aspx?guid=2D7BE2EE-2D0C-4F0E-B15D-C7B7BE9374C5&siteid=yhoof2
*********************************************************

Fri, 14 Nov 2014 18:04:44 GMT ~ ANACOR PHARMACEUTICALS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=anac
*********************************************************

Mon, 10 Nov 2014 00:09:45 GMT ~ 10-Q for Anacor Pharmaceuticals, Inc.


read full: http://www.companyspotlight.com/routers/headline/24675/10004/6414531?cp_code=YAH1&1415578185
*********************************************************

Fri, 07 Nov 2014 22:00:25 GMT ~ ANACOR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/141107/anac10-q.html
*********************************************************

Fri, 07 Nov 2014 21:36:00 GMT ~ Anacor Pharmaceuticals to Present at the 2014 Credit Suisse Healthcare Conference

[Business Wire] - Anacor Pharmaceuticals, Inc. announced today that Paul Berns, the company’s President and Chief Executive Officer, will provide a company overview at the 2014 Credit Suisse Healthcare Conference on Thursday, November 13, 2014 at 9:00 a.m.

read full: http://finance.yahoo.com/news/anacor-pharmaceuticals-present-2014-credit-213600022.html
*********************************************************


$ANAC charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$ANAC company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ANAC/company-info
Ticker: $ANAC
OTC Market Place: Not Available
CIK code: not found
Company name: Anacor Pharmaceuticals, Inc.
Incorporated In:

Business Description:


$ANAC share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$ANAC extra dd links

Company name: Anacor Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ANAC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ANAC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ANAC+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ANAC/news - http://finance.yahoo.com/q/h?s=ANAC+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ANAC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ANAC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ANAC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ANAC
DTCC (dtcc.com): http://search2.dtcc.com/?q=Anacor+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Anacor+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Anacor+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ANAC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ANAC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ANAC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ANAC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ANAC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ANAC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ANAC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ANAC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ANAC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ANAC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ANAC+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ANAC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ANAC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ANAC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ANAC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ANAC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ANAC/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ANAC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ANAC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ANAC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ANAC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ANAC



$ANAC DD Notes ~ http://www.ddnotesmaker.com/ANAC

[maumar]

New all time high. This could go much, much higher if their second drug gets approved next year.

[maumar]

Another breakout? Volume might be too low.

[2014shelby]

Nice. Thanks

[maumar]

https://finance.yahoo.com/news/anacor-pharmaceuticals-announces-commercial-launch-200500814.html

They also have another drug in a phase 3 trial for atopic dermatitis.

[2014shelby]

Yep. Sold some at the peak. What's the current state here?

[maumar]

New all time highs. Anybody out there?

[RealGenius]

700K share AH

[TheFinalCD]

Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the Treatment of Mild-to-Modera...







Print


Alert



Anacor Pharmaceuticals, Inc. (MM) (NASDAQ:ANAC)
Intraday Stock Chart

Today : Thursday 27 February 2014
Click Here for more Anacor Pharmaceuticals, Inc. (MM) Charts.
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) for the topical treatment of mild-to-moderate atopic dermatitis with AN2728 Ointment, 2%, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects 10% - 20% of infants and young children.

“We have reached agreement with the FDA on all major parameters for the Phase 3 trials, which we expect to initiate in the next 60 days,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “Based on the clinical studies conducted to date, we believe AN2728 has the potential to offer patients and physicians a safe and effective topical treatment option for mild-to-moderate atopic dermatitis, providing a potential alternative to treating with topical corticosteroids or topical calcineurin inhibitors.”

Phase 3 Trial Design and Endpoints

Anacor will conduct two multi-center, double-blind, placebo-controlled trials with approximately 750 subjects per trial randomized 2:1 (active:vehicle). Both studies will be conducted at multiple sites and enroll subjects ages two years and up with mild-to-moderate atopic dermatitis. Mild-to-moderate atopic dermatitis is defined as an Investigator Static Global Assessment (ISGA) score of 2 (“mild”) or 3 (“moderate”). The ISGA is a 5-point scale from 0 (“clear”) to 4 (“severe”). AN2728 Ointment, 2% will be applied twice daily for 28 days. The primary efficacy endpoint will be treatment success at Day 29, defined as an ISGA of “Clear” or “Almost Clear” with at least a 2-grade improvement from baseline. Secondary endpoints will include an ISGA of “Clear” or “Almost Clear” at Day 29 as well as time to treatment success. Safety evaluation will include reported adverse events, safety laboratory tests, and vital signs.

Anacor will also initiate a long-term safety trial to evaluate the safety of intermittent use of AN2728 Ointment, 2% for up to 12 months. Subjects who complete either Phase 3 trial will have the option to roll into the long-term safety trial until approximately 500 subjects are enrolled. At least 100 subjects will be enrolled for 12 months and at least 300 subjects will be enrolled for 6 months, during which time subjects will be treated as needed under the direction of the investigator.

Selected Results from Previously Reported Clinical Studies of AN2728 Ointment, 2% in Mild-to-Moderate Atopic Dermatitis

The following four clinical studies of AN2728 in mild-to-moderate atopic dermatitis support the basis for our Phase 3 study design:
• AD-202 – a double-blind, bilateral, vehicle-controlled study in 25 adults in which 52% of AN2728-treated lesions achieved total or partial clearance, defined as an Atopic Dermatitis Severity Index (ADSI) score < 2 versus 16% for vehicle after 28 days of twice-daily treatment. The ADSI score is the sum of the severity scores of five clinical features (erythema, pruritus, exudation, excoriation and lichenification) from 0 (none) to 3 (severe) for each feature, for a total score of 0 to 15. Anacor originally reported the results of this study on December 12, 2011.
• AD-203 – an open-label, whole-body study in 23 adolescents in which 74% of patients achieved an ISGA score of 0 (“clear”) or 1 (“almost clear”) after four weeks of twice-daily treatment. 35% of patients achieved an ISGA score of 0 (“clear”) or 1 (“almost clear”) with a minimum 2-grade improvement after four weeks of twice-daily treatment. Anacor originally reported the results of this study on December 10, 2012.
• AD-204 – a double-blind, bilateral, dose-ranging study in 86 adolescents in which twice daily treatment with AN2728 Ointment, 2% demonstrated the greatest improvement in treating atopic dermatitis lesions. 62% of lesions in this treatment group achieved total or partial clearance, as defined by the ADSI. Anacor originally reported the results of this study on March 21, 2013.
• AD-102 – a maximal use systemic exposure (MUSE) study in patients, ages two to 17 years with atopic dermatitis affecting a large percentage of their body surface area. 47% of patients achieved an ISGA score of 0 (“clear”) or 1 (“almost clear”) with a minimum 2-grade improvement after four weeks of twice-daily treatment with AN2728 Ointment, 2%. 65% of patients achieved an ISGA score of 0 (“clear”) or 1 (“almost clear”) after four weeks of twice-daily treatment with AN2728 Ointment, 2%. Anacor originally reported results of this study on November 12, 2013.

In addition to these four studies, AN2728 has demonstrated safety and efficacy in 14 other Phase 1 and Phase 2 studies. In all studies, AN2728 was generally considered safe and well-tolerated. Most adverse events were mild and largely unrelated to study drug.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. Anacor has also discovered three other compounds that have been out-licensed for further development — one is licensed to Eli Lilly and Company for the treatment of an animal health indication, the second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness) and the third compound is licensed to GlaxoSmithKline, LLC for development in tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit http://www.anacor.com.





Anacor Pharmaceuticals
DeDe Sheel, 650.543.7575
Senior Director, Investor Relations and Corporate Communications

[surf1944]

9:09AM Anacor Pharma Awarded U.S. Government Funding to Discover New Classes of Systemic Antibiotics (ANAC) 13.83 : Co announces has entered into a research agreement with the United States Department of Defense, Defense Threat Reduction Agency to design and discover new classes of systemic antibiotics. A drug discovery consortium formed by Anacor, Colorado State University and the University of California at Berkeley will conduct the research over a three and a half year period. The work is funded by a "3.5 mln award from DTRA's R&D Innovation and Systems Engineering Office which was established to search for and execute strategic investments in innovative technologies for combating weapons of mass destruction.

[surf1944]

The chart does look very much like a top in place, the risk will likely be to the downside for ANAC's next move:

http://stockcharts.com/h-sc/ui?s=anac&p=D&yr=0&mn=6&dy=0&id=p90029751166

[pj McMulligan]

Hey surf! ANAC looks like the perfect short here with the inverted pincher pattern and negative earnings I picked up a starter position today with the bearish SAR signal B-)

[ECole]

JMP-Securities Conference Updates

Interesting comments at conference.. worth a glance


Transcript here

[surf1944]

8:32AM Anacor Pharma reports successful completion of Pre-NDA communications With the FDA for Tavaborole (ANAC) 6.00 : Co announces that it has successfully completed its pre-NDA communications with the FDA related to tavaborole, its drug candidate for the topical treatment of onychomycosis. In its pre-NDA communications, co achieved concurrence from the FDA on the content and format of the proposed NDA for tavaborole including required data related to safety, efficacy, manufacturing and packaging. Anacor remains on schedule to file the NDA in mid-2013.

[mlkrborn]

Anacor Pharmaceuticals Reports First Quarter 2013 Financial Results $5.68
Business WirePress Release: Anacor Pharmaceuticals – Thu, May 9, 2013 4:01 PM EDT


RELATED QUOTES
Symbol Price Change
ANAC 5.68 -0.58

PALO ALTO, Calif.--(BUSINESS WIRE)--

Anacor Pharmaceuticals (ANAC) announced today its financial results for the first quarter ended March 31, 2013.

“It was an eventful first quarter. We reported positive data from our two Phase 3 trials of tavaborole in onychomycosis, and we are on track to file our NDA around the middle of this year. In addition, we reported successful results from our third Phase 2 trial of AN2728 in atopic dermatitis, which informed the most efficacious dosing regimen for our anticipated Phase 3 trials,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “And most recently, we accomplished the goal of our previously scheduled preliminary injunction hearing as Valeant agreed not to launch efinaconazole, its topical product candidate for onychomycosis, if approved, until after our final arbitration hearing in September of this year.”

First Quarter 2013 Highlights and Recent Developments

Clinical

Tavaborole – our lead topical antifungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.
In the first quarter of 2013, we announced the results from two Phase 3 clinical trials in which tavaborole achieved statistically significant and clinically meaningful results on all primary and secondary endpoints.
AN2728 – our lead topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis. Atopic dermatitis is a chronic rash characterized by inflammation and itching and affects an estimated 40 million people in the seven major pharmaceutical markets, including approximately 10% to 20% of infants and young children.
In March 2013, we announced positive results from a Phase 2 dose-ranging trial of AN2728 in adolescents (ages 12 – 17) with mild-to-moderate atopic dermatitis. This was our third Phase 2 study of AN2728 in atopic dermatitis. A clear dose response was demonstrated in this study, with AN2728 ointment, 2.0% BID yielding the greatest improvement, and AN2728 continued to demonstrate an excellent safety profile.

Research Agreement

On April 5, 2013, we entered into a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindness, and lymphatic filariasis, commonly known as elephantiasis) and tuberculosis. Under the agreement, the Gates Foundation will pay Anacor up to $17.7 million over a three-year term to conduct research activities directed at discovering potential drug candidates for these neglected diseases. In addition, the Gates Foundation purchased shares of Anacor’s common stock for net proceeds of approximately $5.0 million.

Corporate

In May 2013, we completed an underwritten public offering of 3,599,373 shares of our common stock, including the exercise of the overallotment option in full by the underwriters, for net proceeds of approximately $21.4 million.
In May 2013, Valeant Pharmaceuticals International, Inc. (Valeant) agreed that the launch of efinaconazole, its topical product candidate for the treatment of onychomycosis, will not occur, if at all, until after the September 2013 arbitration hearing to resolve the breach of contract dispute we initiated with them in October 2012. As a result, the preliminary injunction hearing, which was previously scheduled for May 6-8, 2013, was canceled.

Anticipated Milestones in the Next Twelve Months

Tavaborole, our lead product candidate for the treatment of onychomycosis:
We expect to file a New Drug Application with the FDA for tavaborole in mid-2013.
We currently have a final hearing for our arbitration with Valeant scheduled in September 2013 and anticipate the resolution of the arbitration in the second half of 2013.
We expect to choose a path for commercialization of tavaborole in the second half of 2013.
AN2728, our lead product candidate for the treatment of atopic dermatitis:
We expect to initiate the following two additional safety studies prior to initiating a Phase 3 study in atopic dermatitis:
1. MUSE (maximal use systemic exposure) study in ~ 30 children with atopic dermatitis to measure blood levels when AN2728 is applied under maximal use conditions.
2. TQT (thorough QT) study to assess the effects of AN2728 on electrocardiograms (ECGs) in ~180 healthy volunteers following multiple-dose administration.
We expect to initiate a Phase 3 study in atopic dermatitis in the fourth quarter of 2013 or the first quarter of 2014, with timing dependent on the completion of the MUSE study.

Selected First Quarter 2013 Financial Results

Revenues for the quarter ended March 31, 2013 were $1.7 million, compared to $2.4 million for the comparable period in 2012. The decrease in revenues from 2012 is primarily due to a decrease in research work performed under our research and development agreements, including agreements with not-for-profit organizations for neglected diseases. In addition, in the first quarter of 2013, we did not recognize any revenue from the upfront free received in 2011 under the agreement with Medicis relating to the discovery of potential treatments for acne.

Research and development expenses were $11.2 million for the first quarter of 2013, compared to $12.7 million for the same quarter in 2012. The decrease in research and development expenses from 2012 is comprised of a decrease in clinical expenses for tavaborole and a decrease in research and development related to the Medicis collaboration, partially offset by increases in expenses related to our Lilly animal health programs and other research activities.

General and administrative expenses for the first quarter of 2013 were $4.7 million, compared to $3.4 million for the comparable period in 2012. The increase from 2012 is primarily due to an increase in legal fees resulting from the legal proceedings for our disputes with Valeant.

Cash, cash equivalents and short-term investments totaled $32.4 million at March 31, 2013, compared to $45.5 million at December 31, 2012.

2013 Financial Outlook

We believe that our existing capital resources, including the net proceeds from the sale of our common stock in the Gates Foundation private placement offering in April 2013 and the public stock offering in May 2013, will be sufficient to meet our anticipated operating requirements until at least the end of 2013.

Conference Call and Webcast

Anacor will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT today, during which management will discuss the Company’s financial results and recent developments. The call can be accessed by dialing [phone] (domestic) and [phone] (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the Company’s website at www.anacor.com and will be available for three months following the call.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK ‘052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC, or GSK. GSK has returned all rights to the compound to us and we are considering our options for further development, if any, of this compound. We have also discovered three other compounds that we have out-licensed for further development — two are licensed to Eli Lilly and Company for the treatment of animal health indications and the third compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness). We also have a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit http://www.anacor.com.

[surf1944]

9:02AM Anacor Pharma prices public offering of ~3.129 mln shares of its common stock at $6.39/share (ANAC) 6.38 :

[homebuilder_watcher]

Note today from Canaccord. Didn't help today but their theory is spot on I think raised target to $13.

Their timing was bad but logic sound. "Raising price target to $13 from $8 on Derm expert opinions on recent phase 2B data. We see ANAC's AN2728 for atopic dermatitis as a major value driver for shares going forward....After speaking to dermatologists on their opinions of the March AN2728, we believe there is major upside to our previous estimates. We have increased peak market share to 25% from 20%, as well as increasing AN2728's chance of success from 40 to 50%. Dermatologogists we have spoken with think there is a strong suggestion that AN2728 could be stronger than Elidel and Protopic...phase 2B strongly suggests that AN2728 results in more symptoms relief...

[surf1944]

8:33AM Anacor Pharma signs research agreement with the Bill & Melinda Gates Foundation to discover drug candidates intended to treat two filarial worm diseases and tuberculosis; Gates Foundation will pay co $17.7 mln as well as invest $5 mln in Anacor common stock (ANAC) 6.00 : Co announced that it has signed a research agreement with the Bill & Melinda Gates Foundation to discover drug candidates intended to treat two filarial worm diseases and tuberculosis. Additionally, Anacor will create an expanded library of boron compounds to screen for additional potential drug candidates to treat neglected diseases and will provide access to the expanded library compounds for neglected disease research to the Gates Foundation, and others, including academic, governmental and other non-profit institutions or equivalent entities. Under the agreement, Gates Foundation will pay Anacor $17.7 million as well as invest $5 million in Anacor common stock.

[Jonj1]

A good piece in SA:
Is Anacor's Latest Drug Development A Potential Blockbuster?

http://investorshub.advfn.com/boards/post_new.aspx?board_id=19759

[Jonj1]

Came across this article on ANAC:

http://www.marketwatch.com/story/3-stock-picks-from-the-next-david-einhorn-2013-03-29?pagenumber=2

Michael Castor also summarized his investment thesis in another small-cap stock in his February investor letter: Anacor Pharmaceuticals ANAC -0.62% . He talked about the stock because it lost 12.5% of its value in February, but Castor said he is long-term bullish about the stock. Here is what he said:

"We had only one notable loser in the portfolio in February, Anacor Pharmaceuticals. This is an interesting little company that we like for the long term. We foresee four ways to win with our investment in Anacor.

“First, Anacor has a drug to treat toenail fungus. This product has successfully completed two late-stage clinical trials. It is safe and effective.

[BillBadaass]

ANAC up 33% today? Wheeeeee

[surf1944]

Sold out of ANAC on the big gap & run this morning.....

[surf1944]

7:03AM Anacor Pharma announces positive results from Phase 2 dose-ranging study of AN2728 in adolescents with atopic dermatitis (ANAC) 3.84 : Co announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728. The study included 86 adolescents (ages 12 -- 17) with mild-to-moderate atopic dermatitis, a chronic rash which predominantly affects children and is characterized by inflammation and itching. In this study, lesions treated with AN2728 ointment, 2.0% twice daily for 28 days achieved a 71% improvement from baseline in their Atopic Dermatitis Severity Index (ADSI) score, with 66% of lesions in this treatment group achieving total or partial clearance. AN2728 was generally safe and well-tolerated. Most adverse events were mild and largely unrelated to study drug.

[surf1944]

4:03PM Anacor Pharma beats by $0.09, beats on revs (ANAC) 3.70 -0.01 : Reports Q4 (Dec) loss of $0.36 per share, $0.09 better than the Capital IQ Consensus Estimate of ($0.45); revenues rose 26.6% year/year to $3.28 mln vs the $2.63 mln consensus.

"With the positive data from both Phase 3 trials of tavaborole for the treatment of onychomycosis, we anticipate filing an NDA around the middle of this year, and we will continue to evaluate commercialization options to maximize the value of tavaborole"
"We believe our cash, cash equivalents and short-term investments will be sufficient to meet our anticipated operating requirements until we file our NDA for tavaborole in onychomycosis, which we expect to occur in mid-2013.

[pj McMulligan]

Chart and news quite appealing to me here, are any of yall longing more shares at these levels? tia!




Anacor Pharmaceuticals Announces Positive Results from the Second Phase 3 Trial of Tavaborole for Onychomycosis

Anacor Pharmaceuticals, Inc. (MM) (NASDAQ:ANAC)
Intraday Stock Chart
Today : Thursday 28 February 2013


Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302). Tavaborole is a topical anti-fungal for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States. Results from the first Phase 3 trial (known as Study 301) were announced on January 29, 2013. In both studies, tavaborole achieved statistically significant and clinically meaningful results on all primary and secondary endpoints.

“We are pleased with the results of this study and we are on track with our plans to file an NDA in the middle of this year,” said David Perry, Chief Executive Officer of Anacor. “In both Phase 3 trials, tavaborole demonstrated better efficacy than ciclopirox lacquer, the only approved topical treatment for onychomycosis. Importantly, ciclopirox lacquer requires concomitant nail debridement. If approved, tavaborole could offer patients and prescribers a safe, effective and convenient topical treatment option for onychomycosis.”

“In Study 302, tavaborole achieved a complete cure rate of 9.1% in a patient population that we believe represents the majority of onychomycosis patients. In both of our Phase 3 studies, we allowed enrollment of adult patients of all ages who had up to 60% of their toenail affected by disease. While older patients and those with more extensive disease may be tougher to treat, we believe they represent an important and significant segment of the patient population. Approximately fifty percent of people over the age of 70 have onychomycosis, and often patients don’t seek treatment until the infection has progressed and involves a significant portion of the nail,” said Lee Zane, MD, Vice President of Clinical Development of Anacor. “In addition, 27.5% of patients in Study 302 achieved a completely clear or almost clear nail, which is a very meaningful endpoint to physicians and patients because it represents an excellent clinical response.”

The results at week 52 for each of the Phase 3 studies are summarized in the table below:


Study 301

(reported 1/29/13)

Study 302
(active / vehicle) (active / vehicle)
Primary Endpoint
“Complete cure” (a composite endpoint that requires both a completely clear nail and mycological cure)
6.5% / 0.5%

(p=0.001)




9.1% / 1.5%

(p<0.001)

Secondary Endpoints
“Completely clear” or “almost clear” (=10% clinical involvement) nail
26.1% / 9.3%

(p<0.001)




27.5% / 14.6%

(p<0.001)

Mycological cure (the absence of fungus as determined by a negative potassium hydroxide (“KOH”) examination and a negative fungal culture)
31.1% / 7.2%

(p<0.001)




35.9% / 12.2%

(p<0.001)

“Completely clear” or “almost clear” nail with mycological cure
15.3% / 1.5%

(p<0.001)




17.9% / 3.9%

(p<0.001)

Other Results
Negative fungal culture
87.0% / 47.9%

(p<0.001)




85.4% / 51.2%

(p<0.001)

“Completely clear” or “almost clear” nail and negative culture
24.6% / 5.7%

(p<0.001)




25.3% / 9.3%

(p<0.001)


Tavaborole Phase 3 Study 302 Design

Study 302 enrolled 601 patients in the United States and Canada, randomized two-to-one to receive either tavaborole, 5% solution or vehicle. Eligible patients were at least 18 years of age (with no upper age limit) with a clinical diagnosis of distal subungual onychomycosis involving 20% - 60% of the total area of the target great toenail and positive mycology. Patients were instructed to apply tavaborole solution or vehicle to the target great toenail once daily for 48 weeks. Study 301 had an identical design but enrolled patients in the United States and Mexico. Anacor received a Special Protocol Assessment from the FDA on all major parameters of Studies 301 and 302, including study endpoints.

Safety

Overall, tavaborole was safe and well-tolerated across study subjects. There were no serious adverse events related to study drug. The rate of discontinuations as a result of adverse events was low (0.8% for tavaborole and 0.5% for vehicle) in Study 302.

Conference Call and Webcast

Anacor will host a conference call today at 5:00 p.m. ET / 2:00 p.m. PT to discuss these results. The call can be accessed by dialing [phone] (domestic) and [phone] (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the company’s website at http://www.anacor.com and will be available for three months following the call.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, a topical antifungal for the treatment of onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly known as GSK2251052, or GSK ‘052), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC, or GSK. GSK has returned all rights to the compound to us and we are considering our options for further development, if any, of this compound. We have discovered three other compounds that we have out-licensed for further development — two compounds for the treatment of animal health indications that are licensed to Eli Lilly and Company and AN5568, also referred to as SCYX-7158, for human African trypanosomiasis (HAT, or sleeping sickness), which is licensed to Drugs for Neglected Diseases initiative, or DNDi. We also have a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit http://www.anacor.com.

Forward-Looking Statements

This press release may contain forward-looking statements that relate to future events including the development of tavaborole, timing for filing of a new drug application, or NDA, related to tavaborole and the potential for approval and commercialization of tavaborole. These forward looking statements involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements, including risks related to the planned NDA filing, risks from competition for tavaborole (in particular efinaconazole from Valeant Pharmaceuticals International Inc.), whether the information of the key opinion leaders is representative of the behavior and opinions of other investigators, risk of unforeseen side effects and risks related to regulatory approval and commercialization of new drug candidates. These and other risks are described in more detail in Anacor’s Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission under the heading “Risk Factors” and Anacor’s subsequent Quarterly Reports on Form 10-Q. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

[peterus]

surf your still have shares

[C.C.]

ANAC~ Daily Chart on watch for gap fill :)

[surf1944]

7:03AM Anacor Pharma announces positive results from the first of two Phase 3 trials of tavaborole for onychomycosis (ANAC) 5.17 : Co announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail bed that affects ~ 35 million people in the United States. Tavaborole achieved a high degree of statistical significance on all primary and secondary endpoints.

In this first Phase 3 study (known as Study 301), 6.5% of patients treated with tavaborole met the primary endpoint of "complete cure" vs. 0.5% of patients treated with vehicle (p=0.001) at week 52. "Complete cure" is a composite endpoint that requires both a mycological cure and a completely clear nail.
Among the secondary endpoints, 26.1% of patients treated with tavaborole achieved a "completely clear" or "almost clear" (=10% clinical involvement) nail vs. 9.3% in the vehicle-treated arm (p<0.001) at week 52.
31.1% of patients treated with tavaborole achieved mycological cure vs. 7.2% in the vehicle-treated arm (p<0.001) at week 52. Mycological cure is the absence of fungus as determined by a negative potassium hydroxide ("KOH") examination and a negative fungal culture.
15.3% of patients treated with tavaborole achieved "completely clear" or "almost clear" nail with mycological cure vs. 1.5% in the vehicle-treated arm (p<0.001) at week 52.
In addition to the primary and secondary endpoints noted above, 87.0% of patients treated with tavaborole had a negative fungal culture vs. 47.9% in the vehicle-treated arm (p<0.001) at week 52, and 24.6% of patients treated with tavaborole achieved "completely clear" or "almost clear" nail and negative culture vs. 5.7% in the vehicle-treated arm (p<0.001) at week 52.

[onkelhubert]

sold it EOD @$5.23. didn't like the way it was trading. don't want to be caught, if the P3 results aren't that good. should have sold early that day.

[lovethatgreen]

sold it today

decided not to ride it through

have enough risk on the table presently

had it not been for that, I prolly would have held through data

gl to all that are in

[lovethatgreen]

indeed

[$hellKing]

I have been watching it as well. I think it has room to move too.

[umiak]

been watching in and out for sometime, room to run i think.

[$hellKing]

ANAC has been up as of late but still price seems like a good entry. Its still pretty close to its 52week low. How well do you like this one?

[umiak]

ANAC some quick DD:

ANAC a primer:

32M basic and diluted Q3
36M cash and 22M Oct offering of 4M shares
45M cash by eoy 2012, enought through NDA
will raise money after results for launch

SO WHAT IS THE BIG DEAL?

Current nail fungus FDA approved remedies consist of an oral drug with safety issues requiring liver tests
or a topical application with efficacy problems ranging from 5.5-8.5%. Anacor believes they have solved these problems
with their late phase 111 product Tavaborole.

35M people in the US have the onychomycosis infection. Anacor
believes more patients can be reached by offering a safe, topical anti-fungal with higher efficacy.


PHASE 111 TRIALS:

Quote:
In the fourth quarter of 2011, we completed enrollment in our two identical planned Phase 3 clinical trials for tavaborole in onychomycosis in the Americas. The tavaborole Phase 3 program consists of two double- blind, vehicle-controlled trials enrolling approximately 600 patients each. Vehicle refers to the formulation without the active ingredient. Two-thirds of the patients are randomized to receive tavaborole at the 5.0% concentration, or dose, compared to one-third who will receive vehicle once daily for 48 weeks. The primary efficacy endpoint will be a composite endpoint measuring complete cure of the great toenail at week 52, which is consistent with the FDA requirement for Lamisil. Complete cure requires both a mycologic cure and a completely clear nail. Mycologic cure is achieved when the fungus present in the nail plate is killed by treatment. Achieving a clear nail requires a complete elimination of the diseased portion of the nail by replacement with a new healthy growing nail and nail bed. Given the slow rate of nail growth, which is approximately one to two millimeters per month, the industry standard for conducting Phase 3 clinical trials of onychomycosis is to evaluate the nails over a 12-month period, in order to allow sufficient time for patients to grow a new nail. We expect data from the first of these trials in January 2013 and from the second trial approximately six weeks later.

http://www.clinicaltrials.gov/ct2/results?term=an2690.

CONFERENCE LINK FOR COMPANY PRESENTATION:
http://www.media-server.com/m/p/uetscjzh

[lovethatgreen]

Im in 4.87

[onkelhubert]

added 1k in the last trading seconds @$5.01. higher highs and higher lows for the last three days, and a close above $5.00 EOW.
looking at the chart it looks primed for an upward movement next week.

[lovethatgreen]

appreciate it

[$$$eeker]

AF on $ANAC. http://bit.ly/VMpWOC

[onkelhubert]

he puts some facts about tavaborole on the table, but i didn't check them all. all in all he's pretty neutral, imo.
articel was published 01/15/13.

thestreet

[lovethatgreen]

good ole AF the AH..whats he have to say about this one?

[onkelhubert]

took 1k shares @$4.75 today. having a tight stop just in case they drive it further down. in case of nice P3 results, i think it will fly. not sure about the opposite and how hard it would tank. according to AF and thestreet they will release topline results every day now.

[spottrader]

well maybe not. ANAC stagnant here going into data release and the chart looks like crap.